EVALUATION OF THE ANTIDIABETIC ACTIVITY OF METHANOLIC EXTRACT OF COPTIS TRIFOLIA IN STREPTOZOTOCIN-INDUCED DIABETES RATS
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
The present study aimed to evaluate the antidiabetic, hypolipidemic, and antioxidant activities of the methanolic extract of Coptis trifolia in a streptozotocin-induced hypertensive rat model. Rats were divided into five groups: normal control, Streptozotocin control, standard drug (hydrochlorothiazide), and two doses of Coptis trifolia extract (200 mg/kg and 500 mg/kg). Treatment was administered orally, and parameters including fasting blood glucose, serum insulin, lipid profile, liver glycogen content, antioxidant enzyme levels (GST, GSH, SOD), and body weight changes were measured. Streptozotocin treatment induced significant hyperglycemia, dyslipidemia, oxidative stress, and weight loss. Administration of Coptis trifolia extract significantly reduced fasting blood glucose and improved glucose tolerance, serum insulin levels, and liver glycogen content in a dose-dependent manner. Additionally, the extract normalised serum lipid profiles by lowering total cholesterol, triglycerides, LDL-C, and VLDL-C, while increasing HDL-C. Antioxidant enzyme activities and total protein content were markedly restored by Coptis trifolia treatment, indicating a potent antioxidative effect. The Coptis trifolia methanolic extract exerts multi-faceted protective effects against metabolic disturbances associated with Streptozotocin induced hypertension. This supports its potential therapeutic application as a natural agent for managing diabetes and cardiovascular complications. Keywords: Coptis trifolia , hypertension, hypertension, LDL-C, cholesterols
Fields of Study & Subjects
Natural Antidiabetic Agents Studies
Medicinal Plant Research
Berberine and alkaloids research
Publication details
- Journal / source
- Zenodo (CERN European Organization for Nuclear Research)
- Publication date
- 30 March 2026
- Language
- EN